{"id":"W2955205003","doi":"10.1016/s0140-6736(19)30952-3","title":"Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":298,"is_retracted":false,"has_abstract":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"AbbVie Deutschland","keywords":"Adalimumab; Medicine; Plaque psoriasis; Psoriasis; Double blind; Internal medicine; Dermatology; Physical therapy; Alternative medicine; Placebo; Disease; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003700492,0.0004585079,0.001767041,0.0001615156,0.0001961477,0.00005461563,0.0005017932,0.0001967574,0.000473118],"category_scores_gemma":[0.00001467028,0.000251985,0.0001522892,0.0003192672,0.00008323267,0.0001593015,0.00005462341,0.0003311515,0.0005389011],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001148578,"about_ca_system_score_gemma":0.0001411563,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001326049,"about_ca_topic_score_gemma":0.0002252507,"domain_scores_codex":[0.9976153,0.0005766312,0.0004739927,0.0005357498,0.00013982,0.000658543],"domain_scores_gemma":[0.998426,0.0003508185,0.000293186,0.0007812927,0.00009606559,0.00005263537],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9882967,0.00137941,0.004791932,0.00001207525,0.001499699,0.000006984239,0.0009700104,0.0005308214,0.0002816753,0.00007569446,0.001080951,0.001073978],"study_design_scores_gemma":[0.9891799,0.002274894,0.003720337,0.00007567353,0.0003814139,0.000008529169,0.0001563262,0.00003124883,0.002601458,0.00002272472,0.001149738,0.0003977659],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9905254,0.0002147493,0.00002653471,0.0002283511,0.0005946796,0.006680979,0.0002050013,0.00007900654,0.001445283],"genre_scores_gemma":[0.9974848,0.0000128317,0.0000545391,0.0001676745,0.0001758674,0.0009777417,0.0004026146,0.00004003224,0.0006838815],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006959402,"threshold_uncertainty_score":0.9999933,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02777645246813299,"score_gpt":0.2690698673153367,"score_spread":0.2412934148472037,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}